filmov
tv
Why do Waldenström’s and Myeloma Change from MGUS to Active Disease?
Показать описание
For the past fifteen years, Lymphoma & Myeloma has been the premier forum on the latest advances in lymphoma, myeloma, and other plasma cell neoplasms. Over forty internationally recognized leaders in molecular biology, pathology, immunology, translational and clinical research have been involved to provide expertise and guidance on recent developments in the basic science, translational medicine and clinical trials.
This Congress features an interdisciplinary approach, special lectures, debates and interactive techniques to explore the controversial, the upcoming, and the exciting in myeloma, Waldenstrom’s macroglobulinemia, chronic lymphocytic leukemia, lymphoma and Hodgkin’s disease.
In this presentation, Dr. Irene M. Ghobrial discusses why Waldenstrom's and myeloma change from monoclonal gammopathy of undetermined significance (MGUS) to active disease.
© 2015 Imedex, LLC.
0:28:53
Why do Waldenström’s and Myeloma Change from MGUS to Active Disease?
0:06:24
NORD - Waldenstrom Macroglobulinemia
0:10:35
Multiple Myeloma, Waldenström macroglobulinemia, MGUS, MGRS - Plasma Cell Dyscrasias - Introduction
1:29:13
Advances in Multiple Myeloma and Waldenstrom’s Macroglobulinemia including COVID-19 Update
0:03:26
Impact of MYD88 and CXCR4 status on Waldenström's macroglobulinemia
0:06:08
Multiple Myeloma vs Waldenstrom Macroglobulinemia vs MGUS [USMLE]
0:26:55
New insights into the biology and treatment of Waldenström Macroglobulinemia
0:19:19
Smoldering Myeloma: Who and when to treat?
0:04:07
Challenges associated with Waldenström’s
0:10:08
FDA Approval in Waldenstrom Macroglobulinemia, Priority Review and sNDA in Myeloma, and More
0:01:34
Recent advances in Waldenström’s macroglobulinemia
0:27:21
Waldenstrom's macroglobulinemia therapy in the era of novel therapies
0:02:55
Myeloma Canada InfoVideo Series #35 - Waldenström macroglobulinemia
0:06:45
Multiple Myeloma vs. Waldenstrom: Understanding the Differences
0:24:06
High Risk Myeloma: How and should it be treated differently?
0:01:49
CXCR4 in Waldenström’s macroglobulinemia
0:13:34
DEBATE: What is the treatment choice for Waldenstrom macroglobulinemia? - Bendamustine
0:01:22
Managing challenging patients with Waldenström’s macroglobulinemia
0:20:03
BCMA: Predicting Outcomes and Monitoring MM and CLL
0:01:00
The recent FDA approval of teclistamab for R/R multiple myeloma
0:24:34
What is New in Waldenström Macroglobulinemia? How I Treat it
0:28:27
Fact or Fiction? Myeloma Treatment & Side Effects
0:00:45
FDA approval of teclistamab for R/R multiple myeloma and the value of immunotherapies
0:24:00
What is Multiple Myeloma? | Dr. Rafael Fonseca, M.D. | The Patient Story
Комментарии